(Date:12/14/2009)... and THOUSAND OAKS, Calif., Dec. 14 ... Amgen Inc.(Nasdaq: AMGN ) today announced that ... worldwide rights to Array,s small-molecule glucokinase activator program, ... 1 clinical trial in patients with Type 2 ... the agreement, Array will receive an upfront payment ...
(Date:12/14/2009)... NATICK, Mass., Dec. 14 Boston Scientific Corporation ... of a public offering of $2 billion aggregate principal ... registration statement. The public offering consists of $850 ... million of 6.00 percent notes due January 2020 and ... Boston Scientific plans to use the net proceeds ...
(Date:12/14/2009)... - Results From a Survey Conducted by ... Major Industrialized Countries , , - A ... impacts their enjoyment of the ... arthritis find shopping for gifts, ... difficult to do, ...
(Date:12/11/2009)... CHESTNUT HILL, MA (12/11/2009) Boston College researchers have ... for the first time and successfully harvested the elusive ... to improved solar power efficiency, the authors report in ... . , When light is captured in solar cells, ... states. But in order to snare these charges, the ...
Breaking Biology Technology:Array BioPharma and Amgen Partner in Type 2 Diabetes 2Array BioPharma and Amgen Partner in Type 2 Diabetes 3Array BioPharma and Amgen Partner in Type 2 Diabetes 4Array BioPharma and Amgen Partner in Type 2 Diabetes 5Array BioPharma and Amgen Partner in Type 2 Diabetes 6Array BioPharma and Amgen Partner in Type 2 Diabetes 7Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4Elusive 'hot' electrons captured in ultra-thin solar cells 2... 7 GlaxoSmithKline plc (LSE/NYSE: GSK ) ... by its wholly-owned subsidiary Gemstone Acquisition Corporation for shares ... GNLB ). The tender offer expired at 12:00 ... 2009.The depositary for the tender offer has advised GSK ...
... Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical ... Company will present,data from two ongoing Phase 2 clinical ... Oncology (ASCO) Symposia. , In ... Phase 2 trial,of picoplatin in patients with metastatic colorectal ...
... Jan. 7 Dr. Ryan Burnette, Director of Alliance ... 19, 2009 through January 23, 2009. Dr. Burnette ... for high-containment biomedical labs as a lynchpin to an ... excited to visit Singapore, a progressive country that has ...
Other Biology Technology:GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc. 2Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers 2Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers 3Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar 2Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar 3... results - with a modular approach to ... The ChemStation Plus NDS family provides modular ... and data management, giving you the flexibility ... labs needs now and that can grow ...
... Control at its Best: DASGIPs Process ... Online Changes & comprehensive documentation for ... parameters auch as pH, dissolved oxygen, ... and changeable online. Profiles, e.g. constant ...
... designed for immunological studies, vaccine development, ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive Epitope ... Probe Content Probe content is ...
... designed to meet your needs. Two probe ... per array (2 arrays/1" x 3" glass ... array/slide). Features ... extended length delivers higher sensitivity compared to ...
Biology Products:Biology NavigationMedical Navigation